The Centers for Medicare & Medicaid Services yesterday finalized its proposal to codify how it defines “reasonable and necessary” coverage for items and services furnished under Medicare Parts A and B.

For national and local coverage determinations that have “insufficient evidence to meet the appropriateness criteria,” CMS will consider coverage to the extent the items or services are covered by a majority of commercial insurers.

In comments submitted in November, AHA warned against replacing the appropriateness criteria entirely with a consideration of commercial market coverage, noting that such an approach could reduce coverage in the Medicare program and transparency in coverage determinations. Under the final rule, CMS opted not to replace the appropriateness criteria entirely and will issue draft sub-regulatory guidance on the methodology for determining when and how commercial coverage will be determined relevant.

 

The final rule, which takes effect March 15, also establishes a Medicare coverage pathway for innovative medical devices designated as breakthrough by the Food and Drug Administration. According to CMS, the Medicare Coverage of Innovative Technology pathway will result in four years of national Medicare coverage starting on the date of FDA market authorization or a date within two years of authorization that the manufacturer chooses.

Related News Articles

Headline
The AHA submitted a statement Sept. 17 for a House Ways and Means Committee markup session on a series of health care and other bills. Specifically, the AHA…
Headline
The AHA Sept. 15 expressed support for the Ensuring Access to Essential Providers Act, legislation that would require Medicare Advantage plans to cover…
Headline
The AHA Sept. 15 urged Aetna to rescind its recently announced “level of severity inpatient payment” policy, saying that it “could erode the transparency…
Perspective
Public
Every health care provider strives to deliver their patients the best possible care, but not all providers offer the same level or complexity of care. Current…
Headline
A JAMA internal medicine study published Sept. 8 found that since the COVID-19 pandemic, Medicare Advantage beneficiaries have been experiencing longer…
Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…